A once-daily combination pill, GMRx2, has shown a 40% reduction in the risk of recurrent stroke in patients with a history of hemorrhagic stroke, according to a major clinical trial.

Breakthrough in Stroke Prevention

The innovative tablet combines three established blood pressure medications – telmisartan, amlodipine, and indapamide – into a single, convenient dose. This simplification is designed to enhance patient adherence to treatment, ensuring consistent blood pressure management.

Clinical Trial Results

The research, published in The New England Journal of Medicine, involved 1,670 stroke survivors who had experienced an intracerebral hemorrhage and also had pre-existing high blood pressure. Results demonstrated a substantial decrease – up to 40 percent – in the likelihood of another stroke occurring among these high-risk patients.

Impact on Cardiovascular Disease

Experts recognize these findings as a potential turning point in the fight against cardiovascular disease, responsible for over a quarter of all fatalities in the United Kingdom. The efficacy of combination pills surpasses traditional multi-pill approaches.

Professor Craig Anderson, a neurologist at The George Institute and a key author of the study, stated the results could fundamentally alter blood pressure management following a stroke event.

The Importance of Adherence

Non-adherence to prescribed medication schedules can lead to dangerous fluctuations in blood pressure, sharply elevating the risk of stroke or heart attack. Approximately 100,000 individuals in the UK experience a stroke annually, and cardiovascular disease is implicated in roughly 175,000 deaths each year.

Hypertension, affecting around 14 million adults in the UK and 120 million in the US, is a major underlying factor. The NHS currently prescribes blood pressure medication to over 10 million patients in England and Wales, and an estimated 55 million Americans utilize similar drugs.